{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:01:14Z","timestamp":1789682474622,"version":"4.0.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Microbiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:italic>Trypanosoma cruzi<\/jats:italic>\n                    , the agent of Chagas disease, probably infects tens of millions of people, primarily in Latin America, causing morbidity and mortality. The options for treatment and prevention of Chagas disease are limited and underutilized. Here we describe the discovery of a series of benzoxaborole compounds with nanomolar activity against extra- and intracellular stages of\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    . Leveraging both ongoing drug discovery efforts in related kinetoplastids, and the exceptional models for rapid drug screening and optimization in\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    , we have identified the prodrug AN15368 that is activated by parasite carboxypeptidases to yield a compound that targets the messenger RNA processing pathway in\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    . AN15368 was found to be active in vitro and in vivo against a range of genetically distinct\n                    <jats:italic>T. cruzi<\/jats:italic>\n                    lineages and was uniformly curative in non-human primates (NHPs) with long-term naturally acquired infections. Treatment in NHPs also revealed no detectable acute toxicity or long-term health or reproductive impact. Thus, AN15368 is an extensively validated and apparently safe, clinically ready candidate with promising potential for prevention and treatment of Chagas disease.\n                  <\/jats:p>","DOI":"10.1038\/s41564-022-01211-y","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T12:04:14Z","timestamp":1662379454000},"page":"1536-1546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7907-5667","authenticated-orcid":false,"given":"Angel M.","family":"Padilla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3164-9147","authenticated-orcid":false,"given":"Tsutomu","family":"Akama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Easom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0025-1400","authenticated-orcid":false,"given":"Yvonne","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason S.","family":"Halladay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-6953","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4955-048X","authenticated-orcid":false,"given":"Sarah A.","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4113-7081","authenticated-orcid":false,"given":"Carolyn L.","family":"Hodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K.","family":"Wilkerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0441-1355","authenticated-orcid":false,"given":"Brooke","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0844-088X","authenticated-orcid":false,"given":"Arlene","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifeng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0392-6824","authenticated-orcid":false,"given":"Yiru","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2494-4172","authenticated-orcid":false,"given":"Michael Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9669-2862","authenticated-orcid":false,"given":"Robert T.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9589-5243","authenticated-orcid":false,"given":"Rick L.","family":"Tarleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"1211_CR1","doi-asserted-by":"publisher","first-page":"510","DOI":"10.2174\/156652408785748004","volume":"8","author":"KM Bonney","year":"2008","unstructured":"Bonney, K. M. & Engman, D. M. Chagas heart disease pathogenesis: one mechanism or many? Curr. Mol. Med. 8, 510\u2013518 (2008).","journal-title":"Curr. Mol. Med."},{"key":"1211_CR2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","volume":"18","author":"F Torrico","year":"2018","unstructured":"Torrico, F. et al. Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. Lancet Infect. Dis. 18, 419\u2013430 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1211_CR3","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","volume":"370","author":"I Molina","year":"2014","unstructured":"Molina, I. et al. Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease. N. Engl. J. Med. 370, 1899\u20131908 (2014).","journal-title":"N. Engl. J. Med."},{"key":"1211_CR4","doi-asserted-by":"publisher","first-page":"e34039","DOI":"10.7554\/eLife.34039","volume":"7","author":"FJ Sanchez-Valdez","year":"2018","unstructured":"Sanchez-Valdez, F. J., Padilla, A., Wang, W., Orr, D. & Tarleton, R. L. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. eLife 7, e34039 (2018).","journal-title":"eLife"},{"key":"1211_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1093\/infdis\/jit420","volume":"209","author":"JM Bustamante","year":"2014","unstructured":"Bustamante, J. M., Craft, J. M., Crowe, B. D., Ketchie, S. A. & Tarleton, R. L. New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice. J. Infect. Dis. 209, 150\u2013162 (2014).","journal-title":"J. Infect. Dis."},{"key":"1211_CR6","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.4155\/fmc.09.71","volume":"1","author":"SJ Baker","year":"2009","unstructured":"Baker, S. J. et al. Therapeutic potential of boron-containing compounds. Future Med. Chem. 1, 1275\u20131288 (2009).","journal-title":"Future Med. Chem."},{"key":"1211_CR7","doi-asserted-by":"publisher","first-page":"e1151","DOI":"10.1371\/journal.pntd.0001151","volume":"5","author":"RT Jacobs","year":"2011","unstructured":"Jacobs, R. T. et al. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis. 5, e1151 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR8","doi-asserted-by":"publisher","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","volume":"64","author":"CE Mowbray","year":"2021","unstructured":"Mowbray, C. E. et al. DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis. J. Med. Chem. 64, 16159\u201316176 (2021).","journal-title":"J. Med. Chem."},{"key":"1211_CR9","doi-asserted-by":"publisher","first-page":"5889","DOI":"10.1021\/acs.jmedchem.7b00621","volume":"60","author":"YK Zhang","year":"2017","unstructured":"Zhang, Y. K. et al. Benzoxaborole antimalarial agents. Part 5. Lead optimization of novel amide pyrazinyloxy benzoxaboroles and identification of a preclinical candidate. J. Med. Chem. 60, 5889\u20135908 (2017).","journal-title":"J. Med. Chem."},{"key":"1211_CR10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bmcl.2017.11.028","volume":"28","author":"T Akama","year":"2018","unstructured":"Akama, T. et al. Identification of a 4-fluorobenzyl l-valinate amide benzoxaborole (AN11736) as a potential development candidate for the treatment of Animal African Trypanosomiasis (AAT). Bioorg. Med. Chem. Lett. 28, 6\u201310 (2018).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"1211_CR11","doi-asserted-by":"publisher","first-page":"e740","DOI":"10.1371\/journal.pntd.0000740","volume":"4","author":"AM Canavaci","year":"2010","unstructured":"Canavaci, A. M. et al. In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds. PLoS Negl. Trop. Dis. 4, e740 (2010).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1517\/17460441.2011.573782","volume":"6","author":"JM Bustamante","year":"2011","unstructured":"Bustamante, J. M. & Tarleton, R. L. Methodological advances in drug discovery for Chagas disease. Expert Opin. Drug Discov. 6, 653\u2013661 (2011).","journal-title":"Expert Opin. Drug Discov."},{"key":"1211_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nm1744","volume":"14","author":"JM Bustamante","year":"2008","unstructured":"Bustamante, J. M., Bixby, L. M. & Tarleton, R. L. Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease. Nat. Med. 14, 542\u2013550 (2008).","journal-title":"Nat. Med."},{"key":"1211_CR14","doi-asserted-by":"publisher","first-page":"e1009254","DOI":"10.1371\/journal.ppat.1009254","volume":"17","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. Strain-specific genome evolution in Trypanosoma cruzi, the agent of Chagas disease. PLoS Pathog. 17, e1009254 (2021).","journal-title":"PLoS Pathog."},{"key":"1211_CR15","unstructured":"Guidance for Industry. Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, July 2005 (US FDA, 2005)."},{"key":"1211_CR16","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1371\/journal.pntd.0000316","volume":"2","author":"G Cooley","year":"2008","unstructured":"Cooley, G. et al. High-throughput selection of effective serodiagnostics for Trypanosoma cruzi infection. PLoS Negl. Trop. Dis. 2, e316 (2008).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR17","doi-asserted-by":"publisher","first-page":"e0009141","DOI":"10.1371\/journal.pntd.0009141","volume":"15","author":"AM Padilla","year":"2021","unstructured":"Padilla, A. M. et al. High variation in immune responses and parasite phenotypes in naturally acquired Trypanosoma cruzi infection in a captive non-human primate breeding colony in Texas, USA. PLoS Negl. Trop. Dis. 15, e0009141 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR18","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.4049\/jimmunol.0900852","volume":"183","author":"MC Albareda","year":"2009","unstructured":"Albareda, M. C. et al. Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence. J. Immunol. 183, 4103\u20134108 (2009).","journal-title":"J. Immunol."},{"key":"1211_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.micinf.2010.01.011","volume":"12","author":"GC Olivera","year":"2010","unstructured":"Olivera, G. C. et al. Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina. Microbes Infect. 12, 359\u2013363 (2010).","journal-title":"Microbes Infect"},{"key":"1211_CR20","doi-asserted-by":"publisher","first-page":"e1314","DOI":"10.1371\/journal.pntd.0001314","volume":"5","author":"R Viotti","year":"2011","unstructured":"Viotti, R. et al. Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease. PLoS Negl. Trop. Dis. 5, e1314 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR21","doi-asserted-by":"publisher","first-page":"9616","DOI":"10.1073\/pnas.1807915115","volume":"115","author":"RJ Wall","year":"2018","unstructured":"Wall, R. J. et al. Clinical and veterinary trypanocidal benzoxaboroles target CPSF3. Proc. Natl Acad. Sci. USA 115, 9616\u20139621 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1211_CR22","doi-asserted-by":"publisher","first-page":"e1007315","DOI":"10.1371\/journal.ppat.1007315","volume":"14","author":"D Begolo","year":"2018","unstructured":"Begolo, D. et al. The trypanocidal benzoxaborole AN7973 inhibits trypanosome mRNA processing. PLoS Pathog. 14, e1007315 (2018).","journal-title":"PLoS Pathog."},{"key":"1211_CR23","doi-asserted-by":"publisher","first-page":"e1008932","DOI":"10.1371\/journal.ppat.1008932","volume":"16","author":"F Giordani","year":"2020","unstructured":"Giordani, F. et al. Veterinary trypanocidal benzoxaboroles are peptidase-activated prodrugs. PLoS Pathog. 16, e1008932 (2020).","journal-title":"PLoS Pathog."},{"key":"1211_CR24","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.molmed.2016.07.008","volume":"22","author":"RL Tarleton","year":"2016","unstructured":"Tarleton, R. L. Chagas disease: a solvable problem, ignored. Trends Mol. Med. 22, 835\u2013838 (2016).","journal-title":"Trends Mol. Med."},{"key":"1211_CR25","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/JEP.S267378","volume":"13","author":"AL Mazzeti","year":"2021","unstructured":"Mazzeti, A. L., Capelari-Oliveira, P., Bahia, M. T. & Mosqueira, V. C. F. Review on experimental treatment strategies against Trypanosoma cruzi. J. Exp. Pharmacol. 13, 409\u2013432 (2021).","journal-title":"J. Exp. Pharmacol."},{"key":"1211_CR26","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","volume":"69","author":"CA Morillo","year":"2017","unstructured":"Morillo, C. A. et al. Benznidazole and posaconazole in eliminating parasites in asymptomatic T. cruzi carriers: the STOP-CHAGAS trial. J. Am. Coll. Cardiol. 69, 939\u2013947 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"1211_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14574","volume":"8","author":"E Sonoiki","year":"2017","unstructured":"Sonoiki, E. et al. A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue. Nat. Commun. 8, 14574 (2017).","journal-title":"Nat. Commun."},{"key":"1211_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.15252\/emmm.201607370","volume":"9","author":"A Palencia","year":"2017","unstructured":"Palencia, A. et al. Targeting Toxoplasma gondii CPSF3 as a new approach to control toxoplasmosis. EMBO Mol. Med. 9, 385\u2013394 (2017).","journal-title":"EMBO Mol. Med."},{"key":"1211_CR29","doi-asserted-by":"publisher","first-page":"eaax7161","DOI":"10.1126\/scitranslmed.aax7161","volume":"11","author":"C Swale","year":"2019","unstructured":"Swale, C. et al. Metal-captured inhibition of pre-mRNA processing activity by CPSF3 controls Cryptosporidium infection. Sci. Transl. Med. 11, eaax7161 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1211_CR30","doi-asserted-by":"publisher","first-page":"101871","DOI":"10.1016\/j.isci.2020.101871","volume":"23","author":"V Bellini","year":"2020","unstructured":"Bellini, V. et al. Target identification of an antimalarial oxaborole identifies AN13762 as an alternative chemotype for targeting CPSF3 in apicomplexan parasites. iScience 23, 101871 (2020).","journal-title":"iScience"},{"key":"1211_CR31","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/microorganisms9071408","volume":"9","author":"M Van den Kerkhof","year":"2021","unstructured":"Van den Kerkhof, M. et al. Identification of resistance determinants for a promising antileishmanial oxaborole series. Microorganisms 9, 1408 (2021).","journal-title":"Microorganisms"},{"key":"1211_CR32","doi-asserted-by":"publisher","first-page":"eabb7656","DOI":"10.1126\/scitranslmed.abb7656","volume":"12","author":"JM Bustamante","year":"2020","unstructured":"Bustamante, J. M. et al. A modified drug regimen clears active and dormant trypanosomes in mouse models of Chagas disease. Sci. Transl. Med. 12, eabb7656 (2020).","journal-title":"Sci. Transl. Med."},{"key":"1211_CR33","doi-asserted-by":"publisher","first-page":"e00439","DOI":"10.1128\/AAC.00439-20","volume":"64","author":"MG Alvarez","year":"2020","unstructured":"Alvarez, M. G. et al. New scheme of intermittent benznidazole administration in patients chronically infected with Trypanosoma cruzi: clinical, parasitological, and serological assessment after three years of follow-up. Antimicrob. Agents Chemother. 64, e00439-20 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1211_CR34","doi-asserted-by":"publisher","first-page":"e0009935","DOI":"10.1371\/journal.pntd.0009935","volume":"15","author":"RE Busselman","year":"2021","unstructured":"Busselman, R. E. et al. High incidence of Trypanosoma cruzi infections in dogs directly detected through longitudinal tracking at 10 multi-dog kennels, Texas, USA. PLOS Negl. Trop. Dis. 15, e0009935 (2021).","journal-title":"PLOS Negl. Trop. Dis."},{"key":"1211_CR35","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/1040638719865926","volume":"31","author":"GL Huckins","year":"2019","unstructured":"Huckins, G. L. et al. Trypanosoma cruzi infection in a zoo-housed red panda in Kansas. J. Vet. Diagn. Invest. 31, 752\u2013755 (2019).","journal-title":"J. Vet. Diagn. Invest."},{"key":"1211_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13071-016-1334-7","volume":"9","author":"TT Minuzzi-Souza","year":"2016","unstructured":"Minuzzi-Souza, T. T. et al. Vector-borne transmission of Trypanosoma cruzi among captive neotropical primates in a Brazilian zoo. Parasit. Vectors 9, 39 (2016).","journal-title":"Parasit. Vectors"},{"key":"1211_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s10393-018-1318-5","volume":"15","author":"CL Hodo","year":"2018","unstructured":"Hodo, C. L., Wilkerson, G. K., Birkner, E. C., Gray, S. B. & Hamer, S. A. Trypanosoma cruzi transmission among captive nonhuman primates, wildlife, and vectors. Ecohealth 15, 426\u2013436 (2018).","journal-title":"Ecohealth"},{"key":"1211_CR38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/ilar\/ilx025","volume":"58","author":"LA Cox","year":"2017","unstructured":"Cox, L. A. et al. Nonhuman primates and translational research-cardiovascular disease. ILAR J. 58, 235\u2013250 (2017).","journal-title":"ILAR J"},{"key":"1211_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1590\/S0037-86822003000100014","volume":"36","author":"SS Francolino","year":"2003","unstructured":"Francolino, S. S. et al. New evidence of spontaneous cure in human Chagas\u2019 disease. Rev. Soc. Bras. Med. Trop. 36, 103\u2013107 (2003).","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"1211_CR40","doi-asserted-by":"crossref","unstructured":"Pinto Dias, J. C. et al. Further evidence of spontaneous cure in human chagas disease. Rev. Soc. Bras. Med. Trop. 41, 505\u2013506 (2008).","DOI":"10.1590\/S0037-86822008000500014"},{"key":"1211_CR41","first-page":"33","volume":"87","author":"RL Tarleton","year":"2013","unstructured":"Tarleton, R. L. The role of immunology in combating Trypanosoma cruzi infection and Chagas disease. Rev. Esp. Salud P\u00fablica 87, 33\u201339 (2013).","journal-title":"Rev. Esp. Salud P\u00fablica"},{"key":"1211_CR42","doi-asserted-by":"publisher","first-page":"e0008787","DOI":"10.1371\/journal.pntd.0008787","volume":"14","author":"LF Buss","year":"2020","unstructured":"Buss, L. F. et al. Declining antibody levels to Trypanosoma cruzi correlate with polymerase chain reaction positivity and electrocardiographic changes in a retrospective cohort of untreated Brazilian blood donors. PLoS Negl. Trop. Dis. 14, e0008787 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR43","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1017\/S0031182000065264","volume":"110","author":"S Tomlinson","year":"1995","unstructured":"Tomlinson, S., Vandekerckhove, F., Frevert, U. & Nussenzweig, V. The induction of Trypanosoma cruzi trypomastigote to amastigote transformation by low pH. Parasitology 110, 547\u2013554 (1995).","journal-title":"Parasitology"},{"key":"1211_CR44","doi-asserted-by":"publisher","first-page":"10362","DOI":"10.1021\/acs.jmedchem.9b01429","volume":"62","author":"C Fleau","year":"2019","unstructured":"Fleau, C. et al. Chagas disease drug discovery: multiparametric lead optimization against Trypanosoma cruzi in acylaminobenzothiazole series. J. Med. Chem. 62, 10362\u201310375 (2019).","journal-title":"J. Med. Chem."},{"key":"1211_CR45","doi-asserted-by":"publisher","first-page":"e77","DOI":"10.1371\/journal.ppat.0020077","volume":"2","author":"DL Martin","year":"2006","unstructured":"Martin, D. L. et al. CD8+ T-cell responses to Trypanosoma cruzi are highly focused on strain-variant trans-sialidase epitopes. PLoS Pathog. 2, e77 (2006).","journal-title":"PLoS Pathog."},{"key":"1211_CR46","doi-asserted-by":"publisher","first-page":"e01788","DOI":"10.1128\/mBio.01788-17","volume":"8","author":"LC Soares Medeiros","year":"2017","unstructured":"Soares Medeiros, L. C. et al. Rapid, selection-free, high-efficiency genome editing in protozoan parasites using CRISPR-Cas9 ribonucleoproteins. mBio 8, e01788-17 (2017).","journal-title":"mBio"},{"key":"1211_CR47","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0378-1119(99)00386-8","volume":"239","author":"MP Vazquez","year":"1999","unstructured":"Vazquez, M. P. & Levin, M. J. Functional analysis of the intergenic regions of TcP2beta gene loci allowed the construction of an improved Trypanosoma cruzi expression vector. Gene 239, 217\u2013225 (1999).","journal-title":"Gene"},{"key":"1211_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-10-370","volume":"10","author":"TA Minning","year":"2009","unstructured":"Minning, T. A., Weatherly, D. B., Atwood, J. 3rd, Orlando, R. & Tarleton, R. L. The steady-state transcriptome of the four major life-cycle stages of Trypanosoma cruzi. BMC Genomics 10, 370 (2009).","journal-title":"BMC Genomics"},{"key":"1211_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/dnares\/dsu029","volume":"21","author":"N Osada","year":"2014","unstructured":"Osada, N. et al. The genome landscape of the African green monkey kidney-derived vero cell line. DNA Res. 21, 673\u2013683 (2014).","journal-title":"DNA Res."},{"key":"1211_CR50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"1211_CR51","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2013a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"1211_CR52","unstructured":"National Research Council. Guide for the Care and Use of Laboratory Animals 8th edn (National Academies Press, 2011)."},{"key":"1211_CR53","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.actatropica.2007.05.019","volume":"103","author":"M Piron","year":"2007","unstructured":"Piron, M. et al. Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop. 103, 195\u2013200 (2007).","journal-title":"Acta Trop."},{"key":"1211_CR54","doi-asserted-by":"publisher","first-page":"e2000","DOI":"10.1371\/journal.pntd.0002000","volume":"7","author":"T Duffy","year":"2013","unstructured":"Duffy, T. et al. Analytical performance of a multiplex real-time PCR assay using TaqMan probes for quantification of Trypanosoma cruzi satellite DNA in blood samples. PLoS Negl. Trop. Dis. 7, e2000 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"1211_CR55","doi-asserted-by":"publisher","first-page":"e931","DOI":"10.1371\/journal.pntd.0000931","volume":"5","author":"AG Schijman","year":"2011","unstructured":"Schijman, A. G. et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl. Trop. Dis. 5, e931 (2011).","journal-title":"PLoS Negl. Trop. Dis."}],"container-title":["Nature Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01211-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01211-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T21:05:43Z","timestamp":1668719143000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41564-022-01211-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["1211"],"URL":"https:\/\/doi.org\/10.1038\/s41564-022-01211-y","relation":{},"ISSN":["2058-5276"],"issn-type":[{"value":"2058-5276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"28 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Georgia Research Foundation, Inc. has a financial interest in the intellectual property (IP) detailed in the manuscript including the candidate compounds. Authors from the University of Georgia may receive personal compensation and research funding as governed by the University of Georgia IP Policy if the IP is licensed for commercial use. Authors formerly employed by Anacor Pharmaceuticals or Pfizer were paid employees and shareholders of Anacor\/Pfizer and T.A., D.S.C., J.S.H., R.T.J. and Y.L. are named inventors on issued patents. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}